

## MROQC Breast Project: Clinical Tip Sheet

### Breast Eligibility Criteria

#### Inclusion Criteria:

- **Newly diagnosed**, female breast cancer patients, 18 years and older
- Diagnosed with invasive breast cancer or ductal carcinoma in situ (DCIS)
- To be treated with breast-conserving surgery and **either partial or whole breast radiotherapy**.
- Breast conservation patients treated with neoadjuvant chemotherapy, concurrent or sequential systemic therapy, and radiation to regional nodes are eligible.

#### Exclusion Criteria:

- Patients referred for **post-mastectomy** radiotherapy
- Patients referred for treatment of chest wall **recurrences**
- Any other indication for radiotherapy in a patient who has undergone mastectomy.
- Patients being treated for synchronous **bilateral breast cancer**
- Patients who have been **previously treated with radiation to the thoracic region**.
- Patients with **metastatic breast cancer** are not eligible
- Patients with a second active cancer who have received or will receive therapy within 12 months of their anticipated radiation start date for their breast cancer.

*Additional inclusion and exclusion criteria are listed on page 2 of the breast and lung eligibility criteria document.*

Data Collection Time Points	Pre RT Eval	1 <sup>st</sup> Week of RT	Last Week of RT	3 Months After RT	Annual Post RT end date
Follow-up Windows				2 months-4 months	9 months-15 months
Breast Baseline & Chemo Forms (CDA)	B5 (Baseline)		B6 (Chemo Post RT)	B6 (Update If Needed)	
Patient Questionnaires	B1		B3	B4	B13
Breast RT Toxicity Eval (Provider)		B7	B9	B10	B14

### Data Collection Timepoints- Ultra hypo-fractionation/"5 fractionations"

Time Points	Pre RT Eval	1 <sup>st</sup> Week of RT	Last Week of RT	3 Months After RT	Annual Post RT end date
Follow-up Windows				2 months-4 months	9 months-15 months
Breast Baseline & Chemo Forms (CDA)	B5 (Baseline)		B6 (Chemo Post RT)	B6 (Update If Needed)	
Patient Questionnaires	B1		X	B4	B13
Breast RT Toxicity Eval (Provider)		B7	B9* (RT end date only)	B10	B14

**\*B9: The CDA should only submit the RT end date**

### Project Upgrade Dates

Version #	Upgrade Date
V 1→2	January 2014
V 2→V 3	August 28,2017
V3→V 4	May 7,2019
V4→V 5	February 17,2021

### Project Changes

- **9/10/2025:** Patients with metastatic breast cancer, or those with a second active cancer who have received or will receive therapy within 12 months of their anticipated breast radiation start date, are excluded from the project.
- **3/7/25:** New demographic form added & demographic questions removed from B1. New questions asking how the patient completed the survey added to B1, B3, B4. Responses added to B9, B10, B14 when arm measurement cannot be done.
- **12/12/24:** Questions removed from the B5 form: "other" option removed from axillary surgery question, Lymphovenous bypass removed and tobacco counseling question removed.
- **10/22/24:** Cannabis question added to the B5 form

## MROQC Breast Project: Clinical Tip Sheet

- **10/22/24:** Prone question added to the B7 form
- **9/18/23:** 2-week follow-up is no longer required on patients ending treatment on 9/18/23 onward.
- **8/1/23:** Year 2 and year 3 annual time points removed.
- **12/9/22:** Cannabis questions updated on patient forms and questions added to physician and patient forms to track lymphedema. A question about the type of patient encounter added to all physician forms.
- **6/28/22:** New cannabis use questions added to **B1 & B3** forms and smoking cessation questions added to **B5**.
- **2/17/21:** Patients receiving partial breast radiotherapy are eligible.
- The weekly provider(B8) and weekly patient (B2) forms are no longer collected on breast patients who started treatment on or after **1/1/21**.

### Reminders

- Follow-up times points apply to all breast patients. Follow-up data can be collected during in-person or telehealth appointments.
- ~~Patients with metastatic breast cancer are eligible if bone is not a part of the target.~~ Excluded starting 9/10/2025